Want to see IN:SURAKSHA full AI Analyst Report?
SURAKSHA Stock Chart & Stats
₹300.85
-₹13.40(-3.48%)
At close: 4:00 PM EST
₹300.85
-₹13.40(-3.48%)
Day’s Range― - ―
52-Week Range₹224.10 - ₹333.65
Previous CloseN/A
Volume140.52K
Average Volume (3M)1.23K
Market Cap
₹13.11B
Enterprise Value₹16.27K
Total Cash (Recent Filing)₹263.48M
Total Debt (Recent Filing)₹1.30B
Price to Earnings (P/E)40.8
Beta1.08
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.18
Shares Outstanding52,080,757
10 Day Avg. Volume1,073
30 Day Avg. Volume1,225
Financial Highlights & Ratios
PEG Ratio32.20
Price to Book (P/B)4.85
Price to Sales (P/S)3.82
P/FCF Ratio70.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.2
Revenue Forecast (FY)₹3.68B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue & Operating ProfitabilityConsistent multi-year revenue expansion with operating margin ~17.5% and EBITDA ~30.9% indicates a scalable service model and steady demand for diagnostics. Durable revenue growth supports reinvestment in network capacity and technology, underpinning sustainable cash generation and market positioning over 2–6 months and beyond.
Strong Operating Cash GenerationOperating cash flow materially exceeds accounting profit, reflecting earnings quality and effective cash collection. This persistent cash generation provides flexibility to fund capex, network expansion or working capital without immediate reliance on new equity, supporting durable business operations and funding needs over the medium term.
Manageable Leverage & Balance Sheet ScaleModerate leverage (D/E ~0.53) and growing asset/equity scale provide financial headroom to support expansion while maintaining creditor access. A generally reasonable balance sheet helps absorb cyclical pressures and finance strategic investments, preserving operational continuity and credit optionality across the coming months.
Bears Say
FY26 Margin CompressionSharp gross and net margin compression in FY26 signals deteriorating unit economics that can persist if driven by structural pricing pressure, cost inflation, or adverse mix. Lower margins reduce cash flow per revenue dollar, constraining reinvestment capacity and squeezing returns unless cost dynamics or pricing recover sustainably.
Rising Leverage Trend Since FY25An upward drift in debt since FY25, alongside falling ROE, raises structural financial risk. Higher leverage increases fixed interest obligations and reduces flexibility to fund growth or absorb shocks, making the company more sensitive to margin swings and potentially increasing refinancing risk over the medium term.
Weak & Volatile Free Cash Flow ConversionLow FCF conversion (~20% of net income) and choppy free cash flow history limit the firm's ability to deleverage, return capital, or self-fund expansion. Persistent capex or working-capital needs that suppress FCF reduce financial flexibility and could necessitate external funding, increasing medium-term balance-sheet risk.
Suraksha Diagnostic Ltd. News
SURAKSHA FAQ
What was Suraksha Diagnostic Ltd.’s price range in the past 12 months?
Suraksha Diagnostic Ltd. lowest stock price was ₹224.10 and its highest was ₹333.65 in the past 12 months.
What is Suraksha Diagnostic Ltd.’s market cap?
Suraksha Diagnostic Ltd.’s market cap is ₹13.11B.
When is Suraksha Diagnostic Ltd.’s upcoming earnings report date?
Suraksha Diagnostic Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 4 days.
How were Suraksha Diagnostic Ltd.’s earnings last quarter?
Suraksha Diagnostic Ltd. released its earnings results on May 21, 2026. The company reported ₹1.21 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Suraksha Diagnostic Ltd. overvalued?
According to Wall Street analysts Suraksha Diagnostic Ltd.’s price is currently Overvalued.
Does Suraksha Diagnostic Ltd. pay dividends?
Suraksha Diagnostic Ltd. pays a N/A dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Suraksha Diagnostic Ltd. dividends here
What is Suraksha Diagnostic Ltd.’s EPS estimate?
Suraksha Diagnostic Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suraksha Diagnostic Ltd. have?
Suraksha Diagnostic Ltd. has 52,080,757 shares outstanding.
What happened to Suraksha Diagnostic Ltd.’s price movement after its last earnings report?
Suraksha Diagnostic Ltd. reported an EPS of ₹1.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.73%.
Which hedge fund is a major shareholder of Suraksha Diagnostic Ltd.?
Currently, no hedge funds are holding shares in IN:SURAKSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suraksha Diagnostic Ltd.
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vimta Labs Limited
―